HAI ROBOTICS Marks Milestone with HAIPORT for Order Fulfillment Efficiency
14.12.2021 16:20:00 EET | Business Wire | Press release
HAI ROBOTICS, a global leader in Autonomous Case-handling Robotics (ACR) system for warehouse fulfillment, marked a milestone for its solution of HAIPORT-powered Workstation -- with over 100 sets in operation globally since the product was launched one year ago. The solution has enormously improved order fulfillment efficiency for its customers who were pressured to update their warehousing facilities with higher throughput capacity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005725/en/
HAIPORT-powered Workstation in a warehouse. (Photo: Business Wire)
HAIPORT is an automatic loading and unloading machine that can be docked with HAI ROBOTICS’ autonomous case-handling robots and conveyor workstations.
At a HAIPORT-powered Workstation, multiple loads of totes or cartons are unloaded from the HAIPICK robots at the HAIPORT loader, then transferred onto the conveyor belts for sorting per system orders and moved to the HAIPORT unloader, where they were fetched by robots for the next round of order processing.
The collaboration between HAIPICK robots, HAIPORT, and conveyor belt allows one-stop case-handling from in-bounds to out-bounds. The solution boasts obvious advantages by increasing the throughput of a warehouse.
With case loading and unloading being processed simultaneously at the two sides of a HAIPORT, a single workstation can be expected to handle up to 900 cases per hour, far exceeding that of manual handling. The speed is 16 times faster than the robot-to-conveyor belt transport.
The speed - four to eight cases being loaded in 3 seconds and unloaded in 5s - promises higher case-handling capacity. A single robot’s efficiency can be improved by 30% compared with manual loading/unloading.
Designed to realize direct interaction between HAIPICK robot and conveyor belt, HAIPORT-powered workstation guarantees higher loading and unloading speeds with least human intervention, increasing manual picking efficiency up to 3 times. The use of the workstation can free warehouse staff from tedious manual labor so that they can focus on more important tasks.
Armed with HAI ROBOTICS’ software platform as well as the multi-sensor technology that can monitor a robot’s movement, the workstation can accurately judge if a particular case of goods should be delivered to a workstation or not. Its modular design also grants scalability and flexibility when automating a warehouse. It can be customized and adapted for different uses based on the customer’s requirements. As a result, 30% fewer robots are required if a HAIPORT-powered Workstation is deployed in a warehouse.
HAIPORT-powered workstation has been certified by CE and ETL in compliance with the safety standards for Europe and US markets, respectively. The certifications also evidence that HAI ROBOTICS has been implementing stringent quality control for its products along its own supply chain, in product design and production.
Jeff Zheng, R&D Director at HAI ROBOTICS, said, “HAIPORT-powered Workstation offers an innovative solution for warehousing automation and provides a new way of human-machine interaction. It helps not only increase operational efficiency, but also reduce costs and deliver better ROI. We’re committed to delivering more value to our customers and making their investments worthwhile.”
Thanks to its flexibility, HAIPORT-powered Workstation is suitable for extensive storage scenarios in which medium and small-sized cases are used, such as raw materials, small electronics, apparels, medicine, retails and 3PL industries that have large number of SKUs and demand high order fulfillment efficiency in peak hours with surging e-commerce demands.
About HAI ROBOTICS
HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) system, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse.
The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.
Founded in 2016 with headquarters in Shenzhen, China, HAI ROBOTICS has set up five subsidiaries in Hong Kong SAR, Japan, Singapore, the U.S. and the Netherlands, serving customers from more than 30 countries and regions. It now has over 1,200 staff, more than 50% of whom are engineers. The company has acquired more than 600 global patents for core intellectual properties involving positioning, robot control and warehouse management. In the latest C and D rounds of funding in 2021, the company raised over US$200 million in total.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005725/en/
Contact information
Media Contact:
Anna Zhao
Overseas Brand Communications Manager
anna.zhao@hairobotics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom